Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.130
-0.020 (-1.74%)
At close: Apr 28, 2026, 4:00 PM EDT
1.122
-0.008 (-0.74%)
After-hours: Apr 28, 2026, 7:46 PM EDT
Entera Bio Employees
As of December 31, 2025, Entera Bio had 22 total employees, including 20 full-time and 2 part-time employees. The number of employees increased by 2 or 10.00% compared to the previous year.
Employees
22
Change
2
Growth
10.00%
Revenue / Employee
$1,909
Profits / Employee
-$519,955
Market Cap
51.75M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 22 | 2 | 10.00% | 20 | 2 |
| Sep 30, 2025 | 22 | 2 | 10.00% | 20 | 2 |
| Jun 30, 2025 | 21 | 2 | 10.53% | 19 | 2 |
| Mar 31, 2025 | 20 | 1 | 5.26% | 18 | 2 |
| Dec 31, 2024 | 20 | 2 | 11.11% | 18 | 2 |
| Sep 30, 2024 | 20 | -1 | -4.76% | 18 | 2 |
| Jun 30, 2024 | 19 | -2 | -9.52% | 17 | 2 |
| Mar 31, 2024 | 19 | 1 | 5.56% | 17 | 2 |
| Dec 31, 2023 | 18 | 1 | 5.88% | 17 | 1 |
| Sep 30, 2023 | 21 | 2 | 10.53% | 19 | 2 |
| Jun 30, 2023 | 21 | -1 | -4.55% | 19 | 2 |
| Mar 31, 2023 | 18 | -3 | -14.29% | 18 | 0 |
| Dec 31, 2022 | 17 | -3 | -15.00% | 15 | 2 |
| Sep 30, 2022 | 19 | -4 | -17.39% | 19 | 0 |
| Jun 30, 2022 | 22 | 3 | 15.79% | 22 | 0 |
| Mar 31, 2022 | 21 | 2 | 10.53% | 21 | 0 |
| Dec 31, 2021 | 20 | 2 | 11.11% | 18 | 2 |
| Sep 30, 2021 | 23 | 4 | 21.05% | 23 | 0 |
| Jun 30, 2021 | 19 | 0 | - | 19 | 0 |
| Mar 31, 2021 | 19 | -2 | -9.52% | 19 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 119 |
| MiNK Therapeutics | 23 |
| Atossa Therapeutics | 16 |
| Cingulate | 14 |
| Instil Bio | 14 |
| Rallybio | 14 |
| Nutriband | 13 |
| Kezar Life Sciences | 9 |
ENTX News
- 8 days ago - BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity - GlobeNewsWire
- 8 days ago - Entera Bio Transcript: KOL event - Transcripts
- 14 days ago - Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 - GlobeNewsWire
- 22 days ago - Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners - PRNewsWire
- 26 days ago - Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds - GlobeNewsWire
- 4 weeks ago - Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 weeks ago - Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis - GlobeNewsWire
- 2 months ago - Entera Bio Announces Open Market Purchases of Company Stock by Board Members - GlobeNewsWire